Dyslipidemia

ICD-10 E78 · Disorders of lipoprotein metabolism and other lipidemias

Monitoring plan

National Institute for Health and Care Excellence (NICE) (2024) · NICE NG238

on or starting lipid-lowering treatment · baseline before statins, 2 to 3 months after starting or changing treatment, then annually

“Measure liver transaminase and full lipid profile at 2 to 3 months after starting or changing lipid-lowering treatment. Offer an annual full lipid profile to inform discussions about secondary prevention of CVD.” — NG238 1.11.1, 1.11.9

HDL-C

CVD risk assessment · baseline, then annually

“Measure both total blood cholesterol and high-density lipoprotein (HDL) cholesterol to achieve the best estimate of CVD risk.” — NG238 1.4.1

ALT

on statins · 2 to 3 months after starting, then at 12 months, then only if clinically indicated

“Measure liver transaminase and full lipid profile at 2 to 3 months after starting or changing lipid-lowering treatment. Measure liver transaminase at 12 months, but not again unless clinically indicated.” — NG238 1.11.1, 1.11.2

Triglyceride

elevated result · repeat within 2 weeks if elevated and specialist assessment may be needed

“Repeat testing within 2 weeks for elevated levels requiring specialist assessment.” — NG238 1.4.7

Monitoring plan

European Society of Cardiology / European Atherosclerosis Society (2011) · ESC/EAS Guidelines for the management of dyslipidaemias

LDL-C <115 mg/dL

moderate cardiovascular risk

LDL-C <100 mg/dL

high cardiovascular risk

LDL-C <70 mg/dL

very_high cardiovascular risk

Triglyceride <150 mg/dL

desirable level

HDL-C

risk marker

Sources

Lipid targets only. Extracted from the guideline's treatment-target table; this source file carries file-level citation but no per-row page/quote.